A bioavailability study comparing 3 different AZD1981 tablets

Study identifier:D9830C00020

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open Label, Randomised, 4-way Crossover Study to Investigate the Relative Bioavailability of Single Dose AZD1981 via 3 Different Tablets in Healthy Men and Healthy Women of Non-childbearing Potential

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD1981, current small-particle tablet, AZD1981, new small-particle tablet, AZD1981, new large-particle table

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Apr 2011

Primary Completion Date: 01 May 2011

Study Completion Date: 01 Jun 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Uppsala, Sweden

Arms	Assigned Interventions
Experimental: Treatment A	Drug: AZD1981, current small-particle tablet 3x100 mg per oral, single dose in fasted state
Experimental: Treatment B	Drug: AZD1981, new small-particle tablet 3x100 mg per oral, single dose
Experimental: Treatment C	Drug: AZD1981, new small-particle tablet 3x100 mg per oral, single dose
Experimental: Treatment D	Drug: AZD1981, new large-particle table 3x100 mg per oral, single dose in fasted state

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=721&filename=CSR-D9830C00020.pdf
Download
CSR-D9830C00020.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

001-8002369933

information.center@astrazeneca.com

Investigators

Principal Investigator

Wolfgang Kühn

Quintiles AB, Phase 1 Services